18F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancer

Cancer Imaging

Table 1 EORTC criteria for determining tumor response by PET [19]

Classification	Description
Progressive metabolic disease	• An increase in ¹⁸F-FDG tumor SUV of >25% within the tumor region defined on the baseline scan • Visible increase in the extent of ¹⁸F-FDG tumor uptake (>20% in the longest dimension) • The appearance of new ¹⁸F-FDG uptake in metastatic lesions
Stable metabolic disease	• An increase in tumor ¹⁸F-FDG SUV of <25% • A decrease of <15% and no visible increase in the extent of ¹⁸F-FDG tumor uptake (>20% in the longest dimension)
Partial metabolic response^a	• A decrease in tumor uptake of ¹⁸F-FDG >25% after >1 cycle of treatment
Complete metabolic response	• Complete resolution of ¹⁸F-FDG uptake within the tumor volume so that it is indistinguishable from surrounding normal tissue

EORTC European Organisation for Research and Treatment of Cancer, ¹⁸ F-FDG [¹⁸F]2-fluoro-2-deoxyglucose, PET positron emission tomography, SUV standardized uptake value
^aEORTC criteria also define a decrease in tumor uptake of ¹⁸F-FDG of ≥15% to 25% after 1 cycle of treatment as a partial metabolic response; however, the more stringent 25% threshold was applied to all patients in this study

ISSN: 1470-7330